Company and summary of significant accounting policies.

No definition available.

Name:	abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems
Namespace Prefix:	abio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of patients.

+ References

No definition available.

+ Details

Name:	abio_NumberOfPatients
Namespace Prefix:	abio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of patients company plans to enroll.

+ References

No definition available.

+ Details

Name:	abio_NumberOfPatientsCompanyPlansToEnroll
Namespace Prefix:	abio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Trial endpoint term

+ References

No definition available.

+ Details

Name:	abio_TrialEndpointTerm
Namespace Prefix:	abio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611

+ Details

Name:	us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Stock Split
-URI http://asc.fasb.org/extlink&oid=6525746

+ Details

Name:	us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

+ References

+ Details

Name:	us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=abio_PrivateInvestmentInPublicEntityTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_HealthCareTrustFundAxis=abio_BestTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBAndThreeHeartFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_HealthCareTrustFundAxis=abio_GENETICAFTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company and Summary of Significant Accounting Policies (Details Textual)		6 Months Ended	12 Months Ended
	Jun. 16, 2015 USD ($)	Jun. 30, 2016 USD ($) Patients	Dec. 31, 2016 Patients
Company And Summary Of Significant Accounting Policies Table [Line Items]
Revenues \| $		$ 0
Description of reverse stock split		1-for-7 reverse stock split
Reverse stock split		0.143
Concentrations of credit risk \| $		$ 0
Private Investment In Public Entity Transaction
Company And Summary Of Significant Accounting Policies Table [Line Items]
Proceeds from the issuance of security units \| $	$ 34,200,000
Phase 3 heart failure (HF) trial of Gencaro \| BEST Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients \| Patients		2,708
Phase 2B/Phase 3 \| GENETIC-AF Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients company plans to enroll \| Patients		620
Trial endpoint, term		168 days
Phase 2B \| GENETIC-AF Trial \| Forecast \| Minimum
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients company plans to enroll \| Patients			150